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Background: There is ample evidence of the differences between genders in chronic obstruc-
tive pulmonary disease (COPD). The purpose of this study was to identify the factors that
contribute to these differences.
Methods: This was a multi-center, cross-sectional observational study including 4574 patients
of 40 years of age and older who attended primary care and pulmonary clinics. Data were
collected on COPD characteristics, comorbidities, quality of life as assessed by both the Euro-
QoL 5D questionnaire (EQ-5D) and the Airways Questionnaire 20 (AQ20), and prevalence of
anxiety and depression. Data collected were compared between males and females.
Results: Mean age was 67 years and 740 patients (16.7%) were female. Women were signifi-
cantly younger, had better pulmonary function, and smoked less; however, they showed poorer
quality of life (EQ-5D: 0.6 [SD Z 0.3] versus 0.7 [0.3]; p < 0.001; and AQ20: 10.4 [SD Z 4.6]
versus 9.2 [SD Z 4.5]; p < 0.001) and a higher rate of anxiety (34.5% versus 20.6%;
p < 0.001) and depression (31.7% versus 22.1%; p < 0.001). In a multivariate analysis, female
gender was significantly associated to poorer quality of life (AQ20) but not to a higher rate of
dyspnea.
Conclusion: Women with COPD are younger and have lower rates of impaired lung function;
however, they show poorer quality of life and more frequent COPD-associated anxiety and
depression.
ª 2011 Elsevier Ltd. All rights reserved.maria Sector Zaragoza II, C/Condes de Arago´n, 30, 50009 Zaragoza, Spain. Tel.: þ34 976 76 95 25; fax:
(K. Naberan).
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Several studies have reported that tobacco-induced chronic
lung disease is different between males and females. Males
tend to develop more emphysema, whereas women show
more severe inflammation of the airways; if women develop
emphysema, it is less extensive and more centrally located
than in males.1e3 On average, smoking women with mild
COPDhavesmaller airwayscomparedtomen.Thismaybeone
of the reasons why women have greater bronchial hyper-
responsiveness (BHR) as measured by the methacoline bron-
chial challenge test.4 Women with moderate COPD (GOLD 2)
have been observed to be younger, smoke less, and have
fewer comorbidities and worse walking test scores compared
to men.5 Additionally, women with similar levels of FEV1
exhibit greater dyspnea5-7; however, there seem to be no
differences in symptoms suchaschronic coughandphlegm.7,8
Differences between males and females with COPD are
also seen in health-related quality of life (HRQoL). The
factors that have the greatest impact on HRQoL in men are
dyspnea, exercise capacity and comorbidity, whereas in
women, dyspnea and level of arterial oxygenation are more
important.9 The prevalence of depression and anxiety in
COPD patients is higher than in non-COPD adults10,11;
however, in women, this prevalence is more than twice as
high compared to men.11
The purpose of this study was to identify the differential
characteristics of COPD between men and women in a very
large sample of patients attending primary care and pulmo-
nary clinics.Our aimwas to characterizenot only risk factors,
symptoms and functioning, but also the level of generic and
specific quality of life and impact of depression and anxiety.Methods
Study design
The INSEPOC Study (Spanish acronym for ‘Impact of Socio-
Economic Status on Quality of Life of COPD Patients’) was
a multi-center, cross-sectional observational study. The
primary objective was to characterize the impact of socio-
economic status on quality of life in patients suffering
from COPD. One of the primary objectives was to observe
gender-associated differences in clinical expression of
patients with COPD, varying impact of disease on quality of
life, and potential differences in treatment between
genders. The methods have been described in detail in
a previous report.12 Both family doctors and pulmonologists
were asked to participate in the study to maximize sample
representativeness. Investigators were randomly selected
from the sponsor’s national database, which included
approximately 90% of pulmonologists and 80% of family
doctors registered in Spain. All questionnaires were admin-
istered by the investigators in direct patient interviews and
all information was completed by the research physicians.
Patients
Each investigator was asked to recruit 3 unselected
consecutive patients meeting the following inclusioncriteria: age 40 years or older, diagnosis of COPD according
to the patient’s hospital record, and stable clinical status,
with no exacerbations or treatment with systemic cortico-
steroids and/or antibiotics within 3 months prior to
inclusion.
Patients diagnosed with asthma, pneumonia or chronic
respiratory diseases other than COPD were excluded, as
were patients with dementia, severe psychiatric disorders,
exacerbations of underlying conditions such as heart
disease at inclusion, and chronic conditions involving severe
health impairment.
The study protocol was approved by the Research Ethics
Committee of Hospital Clı´nic, Barcelona, on 10 September
2009 (reference number 2009/5252) and all patients gave
their written informed consent to take part in the study.Measures
The following variables were collected: age, gender,
smoking habit, alcohol intake, weight and height, years
from diagnosis of COPD, spirometric values, clinical symp-
toms of COPD, history of COPD in the last 12 months
(previous exacerbations, emergency room visits and hospi-
talizations), and current treatment. Current physical
activity was measured by asking patients how many
minutes, on average, they walked every day, as described
by Esteban et al.13
Socio-economic status was based on the patients’ levels
of employment and education. The type of occupation was
classified using the International Standard Classification of
Occupations (ISCO).14 Categories were grouped into 5
strata. The first stratum included the most highly qualified
jobs (engineers and university graduates).
Educational level was divided into 3 levels. The lowest
level included illiterate patients and patients who had not
completed their primary education; the intermediate level
included patients with completed primary education; and
the higher level included patients who had attained
secondary and higher education.
The specific questionnaires used in the study were as
follows: (A) Severity of COPD was measured using the COPD
Severity Score (COPDSS), translated and validated in
Spanish.15 This questionnaire includes items about five
aspects of COPD severity: respiratory symptoms, use of oral
steroids and other drugs for COPD, prior hospitalizations or
intubations for respiratory disease and home oxygen
therapy. Each item was previously assigned a weight score
based on clinical aspects of the disease and its expected
contribution to the global severity of COPD. Total scores
range from 0 to 35 with higher values indicating more
severe COPD.16 These scores have demonstrated predictive
value for a higher risk of COPD exacerbations17 and failure
of treatment of exacerbations.18 The dyspnea item of the
COPDSS was used to identify patients with this symptom.
The population was categorized as suffering from dyspnea
if they responded that they had shortness of breath at least
on “hurrying on level ground or walking uphill”. (B)
Comorbidity was assessed using the 19-item Charlson
Comorbidity Index.19 (C) Health-related quality of life
(HRQoL) was measured using the Spanish version of the 5-
item self-administered EuroQoL instrument (EQ-5D).20,21
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of life in patients with chronic disease, including COPD. The
EQ-5D has a descriptive system and a visual analog scale
(VAS) on which patients are asked to report their health
status today. The VAS is a measurement scale ranging from
0 as the worst health status to 100 as the best health status.
The descriptive system comprises five items with three
possible answers for each, assessing the five dimensions of
mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression. By applying the score of the evaluation
set,21 the data can be used to obtain a health status profile
or be converted into a simple utility index (EQ-5D index).
Higher scores on the EQ-5D indicate better health. Specific
quality of life was measured using the Airways Question-
naire 20 (AQ20) in its validated Spanish version.22 The AQ20
is used to measure changes in HRQoL both in COPD and inTable 1 Characteristics of the study patients.
Variable Global
N Z 4552
Ma
N
Age (years) 67.1 (10) 67
Educational level
Low 1946 (43.0) 16
Intermediate 1426 (31.5) 11
High 1157 (25.5) 95
Socio-economic status
E-I 762 (17.9) 66
E-II 552 (12.9) 40
E-III 536 (12.6) 39
E-IV 1053 (24.7) 10
E-V 1363 (32) 12
Smoker (%)
Non-smoker 9.7 4.
Former smoker 64.1 69
Current smoker 26.2 25
Pack-years 44.3 (27.6) 46
Alcohol consumption (%) 53 59
BMI (kg/m2) 28 (4.3) 28
Charlson comorbidity index 1.8 (1.5) 1.
Physical activity (minutes) 75.1 (116.7) 75
Age at diagnosis (years) 57.2 (10.3) 57
Symptoms (%)
Chronic cough 80 80
Wheezing 51.4 49
Phlegm 71.9 73
Dyspnea 55.9 55
FVC (L) 2.67 (0.9) 2.
FVC (%) 70.9 (29) 64
FEV1 (L) 1.62 (0.7) 1.
FEV1 (%) 48.3 (21) 45
FEV1/FVC 0.59 (0.2) 0.
COPDSS 10.6 (5.4) 10
Exacerbations in the past year 2.4 (2.9) 2.
ER visits in the past year 0.75 (1.3) 0.
Hospitalizations in past year 0.32 (0.8) 0.
(A) Lower level: illiterate, incomplete primary education. Intermed
university graduates, senior executives, technical engineers, experts a
II: unqualified assistants, administrative skilled workers. E-III: junior
class skilled workers, third-class skilled workers and specialists. E-V:asthmatic patients. The AQ20 comprises 20 items with ‘yes/
no’ responses and scores range from 0 to 20, with 0 repre-
senting absence of impairment. (D) Anxiety and depression
status was measured using the Hospital Anxiety and
Depression Scale (HAD) in its Spanish version.23 Patients are
asked how they feel at present, including previous days.
The HAD scale has 14 items and each item is answered
differently. A score of 11 or higher indicates the probable
presence of depression or anxiety; a score of 8e10 is only
suggestive; and scores of 7 and below are regarded as being
in the normal range.
Statistical analysis
A descriptive statistical analysis was conducted. Values are
expressed as the mean and standard deviation forles
Z 3792 (83.3%)
Females
N Z 740 (16.7%)
P value
.6 (9.7) 64.2 (11.2) <0.001
39 (43.2) 307 (41.5) 0.413
97 (31.6) 229 (31)
4 (25.2) 203 (27.5)
1 (17.9) 101 (17.6) <0.0001
9 (11.1) 143 (24.9)
1 (10.6) 145 (25.3)
16 (27.5) 37 (6.4)
15 (32.9) 148 (25.8)
2 37.4 <0.001
.9 34.4
.8 28.2
.1 (27.9) 30.8 (20.3) <0.001
.3 21 <0.001
(4.1) 27.8 (5.1) 0.01
8 (1.5) 1.6 (1.4) <0.001
.5 (122.5) 72.9 (82.9) 0.05
.6 (10.1) 55.4 (11.2) <0.001
.1 77.6 0.75
.9 59 <0.001
.3 64.7 <0.001
.1 60.1 0.01
71 (0.9) 2.43 (0.9) <0.001
.99 (18.7) 102.49 (48) <0.001
64 (0.7) 1.54 (0.8) <0.001
.1 (18.1) 65 (27.1) <0.001
58 (0.2) 0.63 (0.2) <0.001
.6 (5.4) 10.3 (5.3) 0.18
4 (2.4) 2.7 (3.6) 0.012
72 (1.3) 0.89 (1.5) 0.002
32 (0.8) 0.30 (0.8) <0.001
iate level: primary education completed. (B) E-I: engineers and
nd certified assistants; administrative supervisors and foremen; E-
skilled workers, administrative assistants. E-IV: first and second-
unskilled workers.
Table 2 Drug treatment for COPD and vaccination rates
according to gender.
Variable Global
(%)
Males
(%)
Females
(%)
P value
Current drug treatment
Short-acting
b2 agonists
64 65.3 61.4 0.06
Long-acting
b2 agonists
87.9 88.4 85.1 0.01
Ipratropium bromide 27.2 27.4 26.2 0.56
Tiotropium bromide 69.4 71.3 59.5 <0.001
Inhaled steroids 86.8 87.1 85.4 0.24
Systemic steroids 10.8 10.7 11.1 0.78
Mucolytics 59.5 58.8 63 0.05
Influenza vaccine 92.5 92.9 90.6 0.03
Pneumococcal vaccine 67.5 67.8 66.2 0.44
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ables. Means and standard deviations were derived for all
variables showing normal distribution. A Student’s t-test
was used to compare values following normal distribution.
A Wilcoxon’s test was used for data not following a normal
distribution. A Student’s repeated-measures t-test was
used on paired data if they showed normal distribution. A
chi-squared (c2) test was used to compare categorical
variables. No interpolation or extrapolation methods were
used for missing data. Correlations between variables ob-
tained and measures of both generic and disease-specific
HRQoL were calculated using the Pearson’s r coefficient.
A logistic regression model was adjusted including
presence or absence of dyspnea as the dependent variable
and the remaining study variables (age at diagnosis, gender,
respiratory symptoms other than dyspnea, lung functionTable 3 Correlations between AQ20 and EQ-5D scores and
patient variables.
Patient variables AQ20 EQ-5D
Age 0.112 0.122
Gender 0.097 0.090
Dyspnea 0.326 0.234
BMI 0.006 0.062
Charlson index 0.242 0.330
COPDSS 0.565 0.605
EQ-5D 0.610 e
AQ20 e 0.610
VAS (patient) 0.566 0.614
VAS (investigator) 0.558 0.605
Cough 0.321 0.201
Wheezing 0.397 0.304
Phlegm 0.263 0.163
HADS anxiety 0.677 0.602
HADS depression 0.639 0.674
FVC (L) 0.087 0.148
FEV1 (L) 0.091 0.164
FVC (%) 0.018 0.018
FEV1 (%) 0.056 0.056parameters and the scores of the different questionnaires)
as dependent variables. An automated stepwise variable
selection method was used for the final fitting of the model.
HRQoL values of the AQ20 were modeled according to the
remaining study variables, as in the model above, using
a generalized linear model; similarly, an automated step-
wise variable selection method was used in the logistic
model. Both models were intended to find out whether
gender was one of the variables that significantly and
independently correlated to the presence of dyspnea as the
major symptom of COPD or to impairment in HRQoL. All
statistical analyses were carried out using the SAS software
package (SAS Institute, Cary, SC), version 9.1 for Windows.Results
Population
A total of 4891 patients were recruited. Of these, 317
(6.5%) were excluded because they met one or more
exclusion criteria. The characteristics of the remaining
4552 patients included in the study are summarized in Table
1. There were 740 females (16.7%), mean age was 67.1
years (SD Z 10) and mean FEV1 (%) was 48.3% (SD Z 21%).
On average, patients walked for 75 min every day
(SD Z 116) and their mean body mass index was 28 kg/m2
(SD Z 4.3).Characteristics of COPD according to gender
Significant differences were seen in most demographic and
clinical characteristics between men and women (Table 1).
Remarkably, women were significantly younger and much
more likely to be non-smokers (37.4% versus 4.2%;
p < 0.001), and those who did smoke had lower rates of
cumulative tobacco consumption (30.8 pack-years versus
46.1; p < 0.001) (Table 1). Women had better lung function
as assessed by FEV1 (%) compared to men (65% versus 45.1%;
p < 0.001). However, when using the COPDSS question-
naire, which assesses severity without pulmonary function,
both genders had similar scores (10.6 versus 10.3;
p Z 0.18). Compared to men, women had more exacer-
bations during the past year (2.7 versus 2.4; pZ 0.012) and
more emergency room visits (0.9 versus 0.7; p Z 0.002).Symptoms and treatment of COPD according to
gender
Wheezing (50% in men versus 59% in women, p < 0.001) and
dyspnea (55.1% in men versus 60.1% in women, p Z 0.01)
were more frequent in females. However, phlegm was more
frequent among males (73.3% versus 64.7%; p < 0.001), as
shown in Table 1.
COPD treatment patterns are shown in Table 2, overall
and for genders. The most significant differences were seen
in the use of tiotropium, which was more frequent in men
than in women (71.3% versus 59.5%; p < 0.001). Influenza
vaccine coverage was high in both genders; however, it was
significantly higher in males (92.9% versus 90.6%; pZ 0.03).
Table 4 Quality of life and anxiety/depression scale results according to gender.
Variable Global
N Z 4565
Males
N Z 3795 (83.3%)
Females
N Z 740 (16.7%)
P value
EQ-5D index 0.7 (0.3) 0.7 (0.3) 0.6 (0.3) <0.001
EQ-5D VAS, patient-reported 59.3 (16.5) 59.7 (16.4) 57.3 (17.3) <0.001
EQ-5D VAS, investigator-
completed
59 (17) 59.2 (16.9) 57.8 (17.8) 0.07
AQ20 9.4 (4.7) 9.2 (4.5) 10.4 (4.6) <0.001
HAD anxiety 7.5 (4.1) 7.2 (4) 9 (4.2) <0.001
HAD depression 7.1 (4.6) 7 (4.6) 8 (4.7) <0.001
Probable cases of anxiety, % 23 20.6 34.5 <0.001
Probable cases of depression, % 23.7 22.1 31.7 <0.001
Impairment of quality of life in women 371No differences were seen between genders in the rates of
pneumococcal vaccination (p Z 0.44); see Table 2.Health-related quality of life and anxiety/
depression
HRQoL scores were consistently poorer in women. Signifi-
cant differences were seen with the generic instrument EQ-
5D, both for the index score and the VAS, and both as
measured by investigators and as reported by patients
(Table 3). Of note, VAS scores were not significantly
different when measured by investigators versus patient
reports. Likewise, when specific quality of life was
measured using the AQ20, women showed significantly
poorer scores (10.4 [SD Z 4.6] versus 9.2 [SD Z 4.7];
p < 0.0019).
The correlation between different demographic and
clinical variables, as well as scores of the different ques-
tionnaires with both generic and disease-specific HRQoL, is
presented in Table 3. The variables that best correlated
with HRQoL were the scores of the HAD questionnaires (r
values between 0.602 and 0.677).Table 5 Multivariate logistic regression model for dyspnea and s
questionnaire for both genders.
Dependent variable: Dyspnea OR 9
Age at diagnosis 0.96 0
COPDSS 0.65 0
AQ20 0.83 0
EQ-5D (patient-completed VAS) 1.04 1
Anxiety (probable case) 10.2 3
Dependent variable: AQ20 Parameter (STD) 9
Gender 0.69 (0.17) 0
EQ-5D 4.03(0.31) 
COPDSS 0.14 (0.01) 0
Dyspnea 1.88 (0.24) 1
Cough 1.53(0.17) 
Wheezing 1.43(0.14) 
Phlegm 0.68(0.15) 
Probable cases of anxiety 0.60(0.10) 
AQ20: Airways Questionnaire 20 (AQ20), a specific quality of life qu
severity. EQ-5D: 5-Item EuroQoL questionnaire. A generic measure of
asked for their health status today.The highest anxiety scale scores were obtained in
women (9 [SD Z 4.2] versus 7.2 [SD Z 4] in men,
p < 0.001). A higher rate of probable cases of anxiety was
found among women (34.5%) compared to men (20.6%),
p < 0.001. The same findings were obtained for the
depression scale (Table 4).Multivariate logistic regression model for dyspnea
and AQ20 scores
The significant independent variables obtained with the
multivariate logistic regression model including presence of
dyspnea as the dependent variable were greater disease
severity (as measured by the COPDSS), older age at diag-
nosis, poorer generic (EQ-5D) and specific (AQ20) quality of
life, and higher anxiety scale scores (Table 5).
Based on the results of simple regression and taking
specific quality of life (AQ20) as the dependent variable,
male gender was observed to be associated with better
scores. Conversely, higher dyspnea rates, greater disease
severity (COPDSS), poorer generic quality of life (EQ-5D),
presence of respiratory symptoms (cough, wheezing,imple regression for quality of life as measured with the AQ20
5% CI P
.9; 1 0.0013
.6; 0.7 <0.0001
.8; 0.9 <0.0001
.02; 1.06 <0.0001
.4; 30.1 <0.0001
5% CI R F p
.35; 1.05 0.0031 16.28 <0.001
4.66; e3.41 0.3740 1465.61 <0.001
.11; 0.17 0.0605 262.40 <0.001
.39; 2.37 0.0098 50.82 <0.001
1.87; e1.18 0.0218 110.56 <0.001
1.71; e1.15 0.0098 149.43 <0.001
0.99; e0.37 0.0030 15.94 < 0.001
0.80; e0.40 0.0065 34.21 <0.001
estionnaire. COPDSS: COPD Severity Score, a measure of COPD
health-related quality of life. VAS: Visual analog scale. Patient is
372 K. Naberan et al.phlegm), and higher anxiety scale scores were significantly
associated to poorer quality of life (Table 5).Discussion
Clinical expression of COPD is clearly different between
men and women. In a sample comprising over 4500 patients
with COPD, of whom 740 were females, we observed that
women with COPD were younger, smoked less, and had
better lung function. However, these women had signifi-
cantly poorer generic and specific HRQoL, reported more
exacerbations and showed higher anxiety and depression
rates. In addition, COPD in women exhibits a different
profile that is more asthma-like, since women show lower
smoking rates, higher rates of dyspnea and wheezing, and
lower rates of cough with sputum production.
The differences observed in the scores of the HRQoL
scales between men and women were significant and above
the threshold considered clinically meaningful22,24; this is
consistent with previous reports of other authors who
observed that women had poorer HRQoL as measured by
the Saint George’s Respiratory Questionnaire (SGRQ), even
though women have less comorbidity and better partial
oxygen pressure.5,25 A study in patients with moderate to
severe COPD also demonstrated that women had poorer
HRQoL, especially on the impact and activity scores of the
SGRQ. Poorer HRQoL in COPD is associated to a higher risk
of hospital readmission,26 which could partly explain the
higher frequency of emergency room visits observed in
women with COPD. Another interesting observation is that
general health status measured by the SF-12 questionnaire
yields poorer results in men with COPD versus men without
COPD; however, similar scores are seen in women with
COPD and in women without COPD.27 This suggests that
perceived health status is slightly different between men
and women with COPD. The regression analysis revealed an
association between poorer specific HRQoL (AQ20) and
severity scores (COPDSS), respiratory symptoms, anxiety
and female gender. This indicates that gender indepen-
dently influences other variables in the perceived health
status of patients with COPD. Conversely, when the same
analysis was undertaken for the single most important
symptom of COPD (i.e., dyspnea), gender was not observed
to significantly and independently influence the perception
of dyspnea. Health status was significantly associated with
dyspnea; the most likely explanation for this is that
increasing dyspnea significantly impairs HRQoL. A higher
prevalence rate of anxiety was seen among women
compared to men (34.5% versus 20.6%), as well as more
cases of depression (31.7% versus 22.1%). This higher
prevalence of anxiety and depression disorders in women
versus men with COPD has been reported in previous
studies using different instruments for diagnosing psychi-
atric disorders, and therefore we can conclude that it is
a well-established finding.10,28e31 Depression in patients
with COPD has been associated, in addition to female
gender, with longer hospital stays, more frequent exacer-
bations, persistence of smoking habit, less physical activity,
and higher mortality,11,32 and possibly with lower treat-
ment adherence.33 This suggests that depression could be,
at least partly, one of the causes underlying more frequentvisits to health services by women who actually have better
lung function, and may explain the younger age of women
diagnosed with COPD compared to men. In this regard, in
our study women had more exacerbations and COPD-
related emergency department visits than men. These
findings are indeed remarkable, because mental disorders
can be managed with pharmacological and/or behavioral
therapy and there is evidence that specialized psychiatric
care in patients with COPD and depression can result in up
to a 30% reduction in 2-year mortality.34 As for symptoms,
dyspnea and wheezing were more frequent in women,
whereas phlegm was more frequent in men. The higher
incidence of wheezing among women may result from their
greater bronchial hyperresponsiveness and FEV1 at similar
ages.4 However, in light of their younger age profile, lower
incidence of and less intensive smoking, higher wheezing
rate and lower cough and phlegm rates, it cannot be ruled
out that some of these women may have been misdiagnosed
as having COPD, and that the study recruited patients who
in reality were asthmatic. Another hypothesis is that
greater bronchial hyperresponsiveness in women may be an
indicator of a higher incidence of an overlap syndrome of
COPD and asthma in smoking females,35 which may have
implications for therapy, as there would be greater
response to treatment with inhaled corticosteroids.35e37 In
spite of this divergent symptom profile, patient treatments
between genders were not significantly different, except
for the use of tiotropium, which was higher in men, in
keeping with previous reports in the Spanish population.29
Another difference in COPD between men and women is
observed in the odds of being diagnosed early. COPD is
often underdiagnosed,38 regardless of gender, but women
are less likely to be diagnosed spirometrically than men,
even with the same symptoms and smoking habits.39 This
shows that physicians still perceive COPD as a masculine
disease and do not think of COPD in women presenting with
the typical COPD symptoms. The increasing prevalence of
COPD and the importance of early detection in women
should become fundamental aspects to be considered in
clinical practice.40 Understanding the differential features
of COPD in women should contribute to reduce the rate of
underdiagnosis and improve the treatment of our female
patients.Conflict of interest
None declared.References
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